Edition:
United Kingdom

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

0.17USD
19 Jul 2019
Change (% chg)

$-0.01 (-6.53%)
Prev Close
$0.18
Open
$0.18
Day's High
$0.18
Day's Low
$0.16
Volume
572,180
Avg. Vol
327,395
52-wk High
$1.29
52-wk Low
$0.15

Latest Key Developments (Source: Significant Developments)

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business
Monday, 15 Jul 2019 

July 15 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS ACQUIRES CANCER GENETICS’ BIOPHARMA SERVICES BUSINESS SUPPORTED BY INVESTMENT FROM AMPERSAND CAPITAL PARTNERS.INTERPACE DIAGNOSTICS GROUP INC - DEAL FOR $23.5 MILLION.INTERPACE DIAGNOSTICS - PRIVATE EQUITY FIRM IN DIAGNOSTIC/BIOPHARMA SECTOR, TO INVEST $27 MILLION IN TWO TRANCHES OF NEWLY ISSUED CONVERTIBLE PREFERRED STOCK.INTERPACE DIAGNOSTICS - UNDER TERMS, MADE ADDITIONAL PAYMENT OF ABOUT $4.5 MILLION TO CANCER GENETICS.  Full Article

Cancer Genetics Reports Q1 Loss Per Share Of $0.90
Monday, 20 May 2019 

May 20 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATE.Q1 LOSS PER SHARE $0.90.Q1 REVENUE FELL 10.8 PERCENT TO $6.8 MILLION.CONTINUE TO WORK WITH RAYMOND JAMES ON A STRATEGIC TRANSACTION.  Full Article

Cancer Genetics, Inc. Announces Proposed Public Offering Of Common Stock
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CANCER GENETICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO PAY ANY AMOUNTS REQUIRED TO PAY TO LENDERS, OTHERS.  Full Article

Cancer Genetics & Certain Units Entered Forbearance & 5th Amendment To Amended & Restated Loan & Security Agreement
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS - CO, CERTAIN UNITS ENTERED FORBEARANCE & 5TH AMENDMENT TO AMENDED & RESTATED LOAN & SECURITY AGREEMENT.CANCER GENETICS INC - AMENDMENT EXTENDS REVOLVING LINE MATURITY DATE TO APRIL 15, 2019.CANCER GENETICS - CO, CERTAIN UNITS ALSO ENTERED INTO FORBEARANCE AGREEMENT & MODIFICATION NO. 4 TO LOAN & SECURITY AGREEMENT DATED MARCH 22, 2017.CANCER GENETICS - AMENDED LOAN AGREEMENT UNDER FORBEARANCE AGREEMENT & MODIFICATION NO. 4 IS INTEREST-ONLY $6 MILLION TERM LOAN, MATURES ON MARCH 22, 2020.  Full Article

Sabby Management, Llc Reports 7.30 Percent Passive Stake In Cancer Genetics As Of Jan 10, 2019
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - :SABBY MANAGEMENT, LLC REPORTS 7.30 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS OF JAN 10, 2019 - SEC FILING.  Full Article

Cancer Genetics Announces Pricing Of Public Offering Of Common Stock
Thursday, 10 Jan 2019 

Jan 9 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS INC ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 13.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $0.225 PER SHARE.  Full Article

Cancer Genetics, Inc. Announces Proposed Public Offering Of Common Stock
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CANCER GENETICS INC - INTENDS TO USE NET PROCEEDS FROM THIS OFFERING TO PAY LENDER FEES AND OTHER COSTS INCURRED.  Full Article

Cancer Genetics Terminates Proposed Merger With Novellusdx
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS TERMINATES PROPOSED MERGER WITH NOVELLUSDX.CANCER GENETICS INC - COMPANY WILL PURSUE ALTERNATIVE STRATEGIC AND FINANCIAL TRANSACTIONS.CANCER GENETICS INC - WILL AGAIN WORK WITH RAYMOND JAMES AS A FINANCIAL ADVISOR IN EVALUATION OF A BROAD RANGE OF FINANCIAL AND STRATEGIC ALTERNATIVES.CANCER GENETICS INC - WE ARE ON TRACK TO DELIVER SOLID OPERATIONAL PERFORMANCE IN Q4 OF 2018.CANCER GENETICS INC - REMAIN CONFIDENT IN STRENGTH OF CORE BUSINESS.CANCER GENETICS INC - TERMINATED DEAL WITH NOVELLUSDX BASED ON DIFFICULTIES IN ADVANCING MERGER PROCESS, CERTAIN OTHER FACTORS.  Full Article

Cancer Genetics Reports Q3 Loss Per Share $0.31
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q3 LOSS PER SHARE $0.31.Q3 REVENUE FELL 26 PERCENT TO $5.9 MILLION.  Full Article

Cancer Genetics Enters Strategic Partnership With Genecast Biotechnology
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Cancer Genetics Inc ::CANCER GENETICS ENTERS STRATEGIC PARTNERSHIP WITH GENECAST BIOTECHNOLOGY TO COMMERCIALIZE TISSUE OF ORIGIN TEST IN CHINA.CANCER GENETICS INC - AGREEMENT WITH GENECAST BIOTECHNOLOGY TO MARKET, DISTRIBUTE AND SELL TISSUE OF ORIGIN (TOO) TEST IN CHINA.  Full Article